Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA, Kohei; Ozguroglu, Mustafa; BANG, Yung-Jue; DI BARTOLOMEO, Maria; MANDALA, Mario; RYU, Min-Hee; FORNARO, Lorenzo; OLESINSKI, Tomasz; CAGLEVIC, Christian; CHUNG, Hyun; MURO, Kei; Goekkurt, Eray; MANSOOR, Wasat; MCDERMOTT, Raymond; SHACHAM-SHMUELI, Einat; CHEN, Xinqun; MAYO, Carlos; KANG, S.; OHTSU, Atsushi; Fuchs, Charles

doi:10.1016/s0140-6736(18)31257-1

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA K., Ozguroglu M., BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., ...Daha Fazla

LANCET, cilt.392, sa.10142, ss.123-133, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 392 Sayı: 10142
Basım Tarihi: 2018
Doi Numarası: 10.1016/s0140-6736(18)31257-1
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.123-133
İstanbul Üniversitesi Adresli: Evet

Özet

Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.